noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

U.S. Senate Committee on Energy[...]

ICYMI: Heinrich and Whitehouse Host Roundtable on Skyrocketing Energy[...]
Hermeus Corp.

Welcome to Atlanta's Newest Airplane Factory
Hermeus Corp.

Hermeus Fully-Funded to Flight with $60 Million U.S. Air Force Partnership

Healthcare

Headlands Research Inc.

06/24/2025 | Press release | Archived content

Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial

Christopher Romero, MD, PhD, FACP, Medical Director at Headlands Research and Principal Investigator at Headlands Research Brownsville, collaborated on a phase 2 study evaluating maridebart cafraglutide (MariTide), a novel long-acting peptide-antibody conjugate designed to treat obesity.

The study found that once-monthly administration of MariTide led to substantial and sustained weight reduction in participants with obesity, with or without type 2 diabetes, and favorable effects on glycemic control.

Read the full publication in the New England Journal of Medicine.

Headlands Research Inc. published this content on June 24, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 18, 2026 at 04:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format